Gene therapy [55, 71, 73, 77], estrogen receptor modulators [79], and exogenous ribitol supplementation [9] improve muscle structure in FKRP-associated dystroglycanopathy models. This evidence concerns the gene ESR1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.